All Axxora Brands
Axxora Brands available in the selected country
Join Axxora
Corporate Profile
Sites
You are logged on as Guest.:  LoginRegister(Empty)
Change country
  United States
  • Home
  • Product Detail
New Products
Brands
Distributors
Support
About

Vascular Endothelial Growth Factor C (C152S mutant) (rat) (recombinant) (His)

 
RLT-R20-017 20 µg 215.00 USD
 
This mutant is lacking binding to VEGFR-2 (KDR) and can serve as a unique tool to investigate the signal transduction of VEGF-C via VEGFR-3 (Flt-4). According to the high degree of homology between growth factors of mammalian species, the protein can also be used for experiments with human cells and for further in vitro and in vivo experiments with other cells and species.

PRODUCT PROPERTIES
Alternative Name:VEGF-C (C152S mutant) (rat) (recombinant) (His)
MW:~18-24kDa.
Source:Produced in insect cells.
Formulation:Lyophilized.
Purity:≥90% (SDS-PAGE)
Endotoxin Content:≤1.2EU/µg protein.
Specific Activity:~5x103 U/mg.
Biological Activity:Stimulates phosphorylation of VEGFR-3 in pig aortic endothelial cells (ED50=150-300ng/ml).
Solubility:Soluble in water and most aqueous buffers.
Reconstitution:Reconstitute with PBS or medium (>50µg/ml).
Short Term Storage:+4°C
Long Term Storage:-20°C
Handling:After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Background / Technical Information:For the Original Manufacturer's data sheet please click here.

TECHNICAL DOCUMENTS

Print as PDF

RELATED PRODUCTS

No related products available

PRODUCT SUPPORT

Technical Service
Bulk Quantity Quote
Customer Service

CATALOG SECTION

Vascular Endothelial Growth Factors...
Vascular Endothelial Growth Factors...
Vascular Endothelial Growth Factors...

Product Literature References

Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats: J. Krishnan, et al.; Cancer Res. 63, 713 (2003), Abstract;
Lymphangiogenic gene therapy with minimal blood vascular side effects: A. Saaristo, et al.; J. Exp. Med. 196, 719 (2002), Abstract;
Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2: V. Kirkin, et al.; Eur. J. Biochem. 268, 5530 (2001), Abstract; Full Text
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice: T. Veikkola, et al.; EMBO J. 20, 1223 (2001), Abstract; Full Text
Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells: S. Marchio, et al.; J. Biol. Chem. 274, 27617 (1999), Abstract; Full Text
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities: V. Joukov, et al.; J. Biol. Chem. 273, 6599 (1998), Abstract; Full Text
Bone Metabolism
Cancer
Cell Cycle
Cell Death / Apoptosis / Autophagy / Necrosis
Chemokines & Cytokines
Cytoskeleton
DNA & Protein Labeling
DNA Regulation / Transcription
Drug Discovery
Dyes / Stains / Fluorescent Probes
Epigenetics
Immunology
Inflammation
Molecular Biology / Genomics
Natural Products / Antibiotics
Neurobiology
Nitric Oxide Pathway
Obesity & Adipokines
Oxidative Stress
Proteasome & Related Complexes
Protein Expression / Modification
Signal Transduction
Stress & Heat Shock Proteins
Ubiquitin & Ubl Signaling
Other Products
another CS2 website
©2019 Axxora, LLC.,
  • Privacy
  • Disclaimer
  • Terms
  • Legal
  • Sitemap
  • Feedback